Department of Public Health and Infectious Diseases, Section of Microbiology, Sapienza University, I-00185 Rome, Italy. Electronic address: email@example.com.
Department of Public Health and Infectious Diseases, Section of Microbiology, Sapienza University, I-00185 Rome, Italy.
NOOS s.r.l., I-00181 Rome, Italy.
Department of Biochemical Sciences, Sapienza University, I-00185 Rome, Italy.
PMID: 26296578 DOI: 10.1016/j.antiviral.2015.08.010
Human rhinoviruses (HRV), the cause of common colds, are the most frequent precipitants of acute exacerbation of asthma and chronic obstructive pulmonary disease, as well as causes of other serious respiratory diseases. No vaccine or antiviral agents are available for the prevention or treatment of HRV infection. Resveratrol exerts antiviral effect against different DNA and RNA viruses. The antiviral effect of a new resveratrol formulation containing carboxymethylated glucan was analyzed in H1HeLa cell monolayers and ex vivo nasal epithelia infected with HRV-16. Virus yield was evaluated by plaque assay and expression of viral capsid proteins by Western blot. IL-10, IFN-β, IL-6, IL-8 and RANTES levels were evaluated by ELISA assay. ICAM-1 was assessed by Western blot and immunofluorescence. Resveratrol exerted a high, dose-dependent, antiviral activity against HRV-16 replication and reduced virus-induced secretion of IL-6, IL-8 and RANTES to levels similar to that of uninfected nasal epithelia. Basal levels of IL-6 and RANTES were also significantly reduced in uninfected epithelia confirming an anti-inflammatory effect of the compound. HRV-induced expression of ICAM-1 was reversed by resveratrol. Resveratrol may be useful for a therapeutic approach to reduce HRV replication and virus-induced cytokine/chemokine production.
Keywords: Human rhinovirus; Inflammatory mediators; Nasal epithelia; Resveratrol.
Copyright © 2015 Elsevier B.V. All rights reserved.